Literature DB >> 8882035

Detection of early asymptomatic esophageal dysfunction in systemic sclerosis using a new scintigraphic grading method.

S A Kaye1, Q H Siraj, J Agnew, A Hilson, C M Black.   

Abstract

OBJECTIVE: To screen patients with systemic sclerosis (SSc) for esophageal disease and to demonstrate a new system of grading dysmotility; to determine the relationship between the symptom of dysphagia and the degree of hypomotility shown by scintigraphy.
METHODS: 301 patients with SSc were studied by esophageal scintigraphy using a semisolid orally ingested bolus to detect esophageal dysfunction and gastroesophageal reflux. A new system of grading was used to quantitate the degree of dysfunction, ranging from grade 0 (normal) to grade 4 (severe abnormality).
RESULTS: 246 (82%) patients in the study population had evidence of esophageal hypomotility. Gastroesophageal reflux was noted in 83 (28%) patient. The largest number of patients (33%) were found to have grade 2 abnormalities. The number of patients with reflux decreased with increasing severity of grade, from grade 2 to grade 4 (35 to 13%). A retrospective study of the symptoms of 50 of the total study population showed that increasing severity of grade correlated with increasing mean duration of SSc. There was no significant relationship between disease subset and the presence or severity of esophageal hypomotility. 60% of patients in grades 1 and 2 (i.e. with observed dysmotility shown on scintigraphy) had no symptoms of dysphagia. In the more severe grades (scan grades 3 and 4), symptoms of dysphagia correlated with increase in grade.
CONCLUSION: Symptoms may be unreliable in judging the presence of extent of esophageal disease in SSc. Esophageal scintigraphy is a useful noninvasive screening test for the detection of asymptomatic disease. The new grading system provides information that rapidly identifies the stage of esophageal disease and gives comparative data for followup and interventional studies.

Entities:  

Mesh:

Year:  1996        PMID: 8882035

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value.

Authors:  Serena Vettori; Salvatore Tolone; Domenico Capocotta; Rossella Chieffo; Veronica Giacco; Gabriele Valentini; Ludovico Docimo
Journal:  Clin Rheumatol       Date:  2018-02-13       Impact factor: 2.980

Review 2.  Recognition and management of scleroderma in children.

Authors:  I Foeldvari; N Wulffraat
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

3.  Prevalence and Associated Impacts of Cervical Esophageal Clearance Issues Post Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC).

Authors:  Raymond Fong; Anna F Rumbach; Elizabeth C Ward
Journal:  Dysphagia       Date:  2019-04-15       Impact factor: 3.438

4.  Clinical applications of oro-pharyngo-oesophageal scintigraphy in the study of dysphagia.

Authors:  B Fattori; M Grosso; F Ursino; F Matteucci; V Mancini; E Rizza; V Mattone; G Mariani; A Nacci
Journal:  Acta Otorhinolaryngol Ital       Date:  2007-08       Impact factor: 2.124

Review 5.  Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis.

Authors:  Daniel E Furst; Yolanda Braun-Moscovic; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

Review 6.  Evaluation and management of esophageal manifestations in systemic sclerosis.

Authors:  Konstantinos Denaxas; Spyros D Ladas; George P Karamanolis
Journal:  Ann Gastroenterol       Date:  2018-01-18

7.  Scintigraphic evaluation of oesophageal transit during radiotherapy to the mediastinum.

Authors:  Giuseppe Sasso; Pierfrancesco Rambaldi; Francesco S Sasso; Vincenzo Cuccurullo; Paola Murino; Paolo Puntieri; Hugo R Marsiglia; Luigi Mansi
Journal:  BMC Gastroenterol       Date:  2008-11-05       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.